Relzomostat is a MetAP2 inhibitor, specifically targeting methionine aminopeptidase 2. It holds potential in research concerning obesity, type 2 diabetes, and other conditions associated with obesity.
A3051, is a robust and orally active inhibitor of CXXC5-DVL with an IC 50 of 63.06 nM. Its applications include research into phenotypes associated with obesity, diabetes, and NASH that are induced by high fat diet (HFD) and methionine-choline deficient diet (MCD).